Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia

被引:0
|
作者
Yun, Ji Hyun [1 ]
Chang, Euijin [2 ]
Bae, Seongman [2 ,3 ]
Jung, Jiwon [2 ]
Kim, Min Jae [2 ]
Chong, Yong Pil [2 ]
Kim, Sung-Han [2 ]
Choi, Sang-Ho [2 ]
Lee, Sang-Oh [2 ]
Kim, Yang Soo [2 ,3 ]
机构
[1] Konkuk Univ, Sch Med, Dept Internal Med, Div Infect Dis,Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Div Infect Dis, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Ctr Antimicrobial Resistance & Microbial Genet, Seoul, South Korea
来源
MICROBIOLOGY SPECTRUM | 2024年 / 12卷 / 08期
关键词
hVISA; vancomycin; treatment failure; risk factors; age; severity; minimal inhibitory concentration; MINIMUM INHIBITORY CONCENTRATIONS; METHICILLIN-RESISTANT; CLINICAL-FEATURES; INFECTIONS; STRAINS; HETERORESISTANCE; SUSCEPTIBILITY; DEFINITION; CRITERIA;
D O I
10.1128/spectrum.00333-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infection is increasing and is associated with vancomycin treatment failures. However, studies investigating the risk factors for treatment failure in hVISA infection are limited. Patients with hVISA bacteremia treated with vancomycin over 7 days between August 2008 and June 2020 were enrolled in this study. Clinical and microbiological characteristics were compared between vancomycin treatment failure and success groups to identify the risk factors for vancomycin treatment failure. Among the 180 patients with hVISA bacteremia, 102 patients treated with vancomycin over 7 days were included. Vancomycin treatment failed in 80 (78%) patients. Patients in the vancomycin treatment failure group were older (P < 0.001) and more frequently had solid cancer (P = 0.04) than those in the vancomycin treatment success group. Solid organ transplantation (SOT) was more frequent (P < 0.001) in the vancomycin treatment success group. The Charlson comorbidity index (P = 0.01) and Acute Physiology and Chronic Health Evaluation II scores (P < 0.001) were higher in the vancomycin treatment failure group. In multivariate analysis, independent risk factors for vancomycin treatment failure were old age and severity of bacteremia. SOT and vancomycin minimal inhibitory concentration (MIC) <= 1.0 mg/L using the broth microdilution (BMD) method were associated with successful vancomycin treatment. Old age and infection severity were independent risk factors for vancomycin treatment failure. Vancomycin MIC using the BMD method is an important risk factor for vancomycin treatment failure, and its use should be considered in hVISA bacteremia. IMPORTANCE In this study, we assessed the clinical and microbiological characteristics of heterogeneous vancomycin-intermediated Staphylococcus aureus (hVISA) bacteremia and identified risk factors for vancomycin treatment failure. We found that advanced age and severity of infection were independent risk factors for vancomycin treatment failure. On the other hand, solid organ transplantation and a low vancomycin minimal inhibitory concentration were associated with successful vancomycin treatment. This study highlights the importance of vancomycin minimal inhibitory concentration in hVISA bacteremia.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection
    Casapao, Anthony M.
    Leonard, Steven N.
    Davis, Susan L.
    Lodise, Thomas P.
    Patel, Nimish
    Goff, Debra A.
    LaPlante, Kerry L.
    Potoski, Brian A.
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (09) : 4252 - 4259
  • [32] Prevalence and charactenistics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center
    Maor, Yasmin
    Rahav, Galia
    Belausov, Natasha
    Ben-David, Debby
    Smollan, Gill
    Keller, Nathan
    JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (05) : 1511 - 1514
  • [33] Exposure of Staphylococcus aureus to Subinhibitory Concentrations of β-Lactam Antibiotics Induces Heterogeneous Vancomycin-Intermediate Staphylococcus aureus
    Roch, Melanie
    Clair, Perrine
    Renzoni, Adriana
    Reverdy, Marie-Elisabeth
    Dauwalder, Olivier
    Bes, Michele
    Martra, Annie
    Freydiere, Anne-Marie
    Laurent, Frederic
    Reix, Philippe
    Dumitrescu, Oana
    Vandenesch, Francois
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (09) : 5306 - 5314
  • [34] Etest Methods for Screening Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) strains
    Min Young Lee
    Woo In Lee
    Myeong Hee Kim
    So Young Kang
    Young Jin Kim
    Current Microbiology, 2020, 77 : 3158 - 3167
  • [35] Septic arthritis caused by vancomycin-intermediate Staphylococcus aureus
    Lu, JJ
    Lee, SY
    Hwa, SY
    Yang, AH
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) : 4156 - 4158
  • [36] Resistance and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus
    Liang, Jin
    Hu, Yuanfang
    Fu, Mingxia
    Li, Na
    Wang, Fengxia
    Yu, Xiaojun
    Ji, Bing
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 379 - 388
  • [37] Survival of vancomycin-intermediate Staphylococcus aureus on hospital surfaces
    Zarpellon, M. N.
    Gales, A. C.
    Sasaki, A. L.
    Selhorst, G. J.
    Menegucci, T. C.
    Cardoso, C. L.
    Garcia, L. B.
    Tognim, M. C. B.
    JOURNAL OF HOSPITAL INFECTION, 2015, 90 (04) : 347 - 350
  • [38] Biofilms: A developmental niche for vancomycin-intermediate Staphylococcus aureus
    Chapman, Jenelle E.
    George, Shilpa E.
    Wolz, Christiane
    Olson, Michael E.
    INFECTION GENETICS AND EVOLUTION, 2024, 117
  • [39] Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure
    Kelley, Peter G.
    Gao, Wei
    Ward, Peter B.
    Howden, Benjamin P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (05) : 1057 - 1060
  • [40] Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant Staphylococcus aureus
    Capin, Busra Betul Ozmen
    Tekeli, Alper
    Karahan, Zeynep Ceren
    MICROBIAL DRUG RESISTANCE, 2020, 26 (03) : 238 - 244